News

Pfizer's 7.5% Dividend: Income Haven or House of Cards?
CompanyOverview\|NYSE:PFE] A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income- ...
Clinical Trials Arena4d
Astellas and Pfizer’s Xtandi combo reduces death risk in prostate cancer trial
Astellas and Pfizer's Xtandi plus ADT showed a decrease in mortality risk in a metastatic hormone-sensitive prostate cancer ...
BioPharma Dive5d
FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study
An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.
Fierce Pharma5d
FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population
In a somber end to an FDA advisory committee’s two-day scouring of multiple drugmakers’ oncology data, Pfizer’s pitch to ...
MedPage Today5d
FDA Panel Votes Against Broad Talazoparib-Enzalutamide Label in Prostate Cancer
An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib ...
BioSpace5d
Pfizer’s Talzenna Expansion Fails To Earn FDA Advisory Committee’s Support
The FDA’s independent advisors found Pfizer’s data lacked the precision needed to establish the efficacy of Talzenna in ...
Endpoints News5d
FDA ad­comm votes unan­i­mous­ly against Pfiz­er's prostate can­cer drug com­bo
The FDA’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee vot­ed 8-0 against a new in­di­ca­tion for Pfiz­er’s Talzen­na in ...
pharmaphorum5d
Mixed outcomes for pharma in big week for FDA adcomms
For J&J, there was a positive outcome as the Oncologic Drugs Advisory Committee (ODAC) voted six to two in favour of approval ...
Pfizer bid to expand Talzenna use in prostate cancer questioned by FDA panel
Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate ...
Morningstar2mon
Orbis Medicines Names Veteran R&D Leader Mikael Dolsten Board Chair
Prior to his tenure at Pfizer, Dr. Dolsten served in leadership ... polymerase (PARP) inhibitor Talzenna, the vascular endothelial growth factor receptor (VEGFR) inhibitor Inlyta (axitinib ...
The American Journal of Managed Care3mon
TALAPRO-2 Overall Survival Data Suggest New Standard of Care in mCRPC, Regardless of Genomic Status
Final data from TALAPRO-2 (NCT03395197), a phase 3 trial of talazoparib (Talzenna; Pfizer) and enzalutamide (Xtandi; Astellas/Pfizer) in men with metastatic castration-resistant prostate cancer ...